LT2296663T - Deriniai, apimantys metotreksatą ir dhodh inhibitorius - Google Patents

Deriniai, apimantys metotreksatą ir dhodh inhibitorius

Info

Publication number: LT2296663T
Authority: LT; Lithuania
Prior art keywords: methotrexate; combinations; dhodh inhibitors; dhodh; inhibitors
Prior art date: 2008-06-20

Application number

LTEP09765623.5T

Other languages

English (en)

Inventor

Nuria Godessart Marina

Maria Pilar Pizcueta Lalanza

Original Assignee

Almirall, S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-20

Filing date

2009-06-18

Publication date

2017-09-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39930498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2296663(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-18 Application filed by Almirall, S.A. filed Critical Almirall, S.A.

2017-09-25 Publication of LT2296663T publication Critical patent/LT2296663T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Enzymes And Modification Thereof (AREA)

LTEP09765623.5T 2008-06-20 2009-06-18 Deriniai, apimantys metotreksatą ir dhodh inhibitorius LT2296663T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08382022A EP2135610A1 (en)	2008-06-20	2008-06-20	Combination comprising DHODH inhibitors and methotrexate
PCT/EP2009/004404 WO2009153043A1 (en)	2008-06-20	2009-06-18	Combinations comprising methotrexate and dhodh inhibitors

Publications (1)

Publication Number	Publication Date
LT2296663T true LT2296663T (lt)	2017-09-25

Family

ID=39930498

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP09765623.5T LT2296663T (lt)	2008-06-20	2009-06-18	Deriniai, apimantys metotreksatą ir dhodh inhibitorius

Country Status (35)

Country	Link
US (1)	US8865728B2 (lt)
EP (2)	EP2135610A1 (lt)
JP (1)	JP5507551B2 (lt)
KR (1)	KR101675601B1 (lt)
CN (1)	CN102065866B (lt)
AR (1)	AR072174A1 (lt)
AU (1)	AU2009259625B2 (lt)
BR (1)	BRPI0909995A2 (lt)
CA (1)	CA2728976C (lt)
CL (1)	CL2010001359A1 (lt)
CO (1)	CO6321267A2 (lt)
CY (1)	CY1119643T1 (lt)
DK (1)	DK2296663T3 (lt)
EA (1)	EA020193B1 (lt)
ES (1)	ES2641168T3 (lt)
HR (1)	HRP20171667T1 (lt)
HU (1)	HUE036639T2 (lt)
IL (1)	IL209267A (lt)
LT (1)	LT2296663T (lt)
ME (1)	ME02903B (lt)
MX (1)	MX2010013409A (lt)
MY (1)	MY155249A (lt)
NO (1)	NO2296663T3 (lt)
NZ (1)	NZ589089A (lt)
PE (1)	PE20110149A1 (lt)
PL (1)	PL2296663T3 (lt)
PT (1)	PT2296663T (lt)
RS (1)	RS56584B1 (lt)
SG (2)	SG189810A1 (lt)
SI (1)	SI2296663T1 (lt)
TW (1)	TWI440462B (lt)
UA (1)	UA114388C2 (lt)
UY (1)	UY31897A1 (lt)
WO (1)	WO2009153043A1 (lt)
ZA (1)	ZA201008041B (lt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2319596B1 (es) *	2006-12-22	2010-02-08	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es)	2007-08-10	2009-01-30	Almirall Lab	Nuevos derivados de ácido azabifenilaminobenzoico
AU2009313053A1 (en) *	2008-11-07	2010-05-14	4Sc Ag	Combinational therapy comprising DHODH inhibitor and methotrexate for treating autoimmune disease
EP2210615A1 (en) *	2009-01-21	2010-07-28	Almirall, S.A.	Combinations comprising methotrexate and DHODH inhibitors
EP2239256A1 (en)	2009-03-13	2010-10-13	Almirall, S.A.	Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en)	2009-10-16	2011-04-27	Almirall, S.A.	Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
US8686048B2 (en) *	2010-05-06	2014-04-01	Rhizen Pharmaceuticals Sa	Immunomodulator and anti-inflammatory compounds
EP2457900A1 (en)	2010-11-25	2012-05-30	Almirall, S.A.	New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2012109329A2 (en)	2011-02-08	2012-08-16	Children's Medical Center Corporation	Methods for treatment of melanoma
EP2518071A1 (en)	2011-04-29	2012-10-31	Almirall, S.A.	Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en)	2011-04-29	2012-10-31	Almirall, S.A.	Pyrrolotriazinone derivatives as PI3K inhibitors
EP2526945A1 (en)	2011-05-25	2012-11-28	Almirall, S.A.	New CRTH2 Antagonists
EP2548863A1 (en)	2011-07-18	2013-01-23	Almirall, S.A.	New CRTh2 antagonists.
EP2548876A1 (en)	2011-07-18	2013-01-23	Almirall, S.A.	New CRTh2 antagonists
CN103826624A (zh) *	2011-08-30	2014-05-28	富山化学工业株式会社	类风湿性关节炎等自身免疫疾病的处置的改善方法
EP2594271A1 (en) *	2011-11-21	2013-05-22	Almirall, S.A.	2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
WO2014060431A1 (en)	2012-10-16	2014-04-24	Almirall, S.A.	Pyrrolotriazinone derivatives as pi3k inhibitors
UY35332A (es)	2013-02-15	2014-11-28	Almirall Sa	Derivados de pirrolotriazina como inhibidores de pi3k
CN103315985A (zh) *	2013-05-16	2013-09-25	南京市鼓楼医院	Fingolimod在制备抑制肝癌肝内转移药物中的应用
EP3368896A1 (en) *	2015-10-30	2018-09-05	FMC Corporation	Dihydroorotate dehydrogenase inhibitor compositions effective as herbicides
CN108524482B (zh) *	2017-03-02	2022-11-25	中国科学院上海药物研究所	2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途
WO2019012030A1 (en)	2017-07-13	2019-01-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
US20220227720A1 (en)	2019-05-07	2022-07-21	Universitat Hamburg	Dhodh inhibitors and their use as antiviral agents
KR20230116779A (ko) *	2020-10-15	2023-08-04	아슬란 파마슈티컬스 피티이 엘티디	디히드로오로테이트 헤하이드로즈네이즈(dhodh) 저해제를 이용한 자가면역 질환의 치료
CN116940359A (zh) *	2020-10-15	2023-10-24	亚狮康私人有限公司	用二氢乳清酸脱氢酶（dhodh）抑制剂治疗自身免疫病
EP4119138A1 (en)	2021-07-12	2023-01-18	Universität Hamburg	Dhodh inhibitors and their use as antiviral agents
JP2025513444A (ja) *	2022-04-21	2025-04-24	アスランファーマシューティカルズピーティーイーリミテッド	自己免疫性皮膚疾患の治療

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE209518T1 (de)	1995-06-21	2001-12-15	Asta Medica Ag	Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator
DE19547648A1 (de) *	1995-12-20	1997-06-26	Hoechst Ag	Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) *	1996-03-20	1997-09-25	Hoechst Ag	Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9804343D0 (en)	1998-02-27	1998-04-22	Univ Cardiff	Chemical compounds
SK17632001A3 (sk)	1999-06-10	2003-03-04	Warner-Lambert Company	Liečivo na liečbu Alzheimerovej choroby, inhibíciu agregácie amyloidového proteínu a spôsob na zobrazenie depozít amyloidu
PT1381356E (pt)	2001-04-05	2008-07-24	Aventis Pharma Inc	Utilização de (4' -trifluorometilfenil) - amida do ácido (z) -2- ciano-3-hidroxi-but-2-enóico para tratamento da esclerose múltipla
PE20030120A1 (es) *	2001-06-19	2003-02-12	Merck & Co Inc	Sal amina de un antagonista de receptor de integrin
DE10129703A1 (de)	2001-06-22	2003-01-02	Sofotec Gmbh & Co Kg	Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
MXPA04000224A (es) *	2001-07-10	2005-07-25	4Sc Ag	Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
DE10202940A1 (de)	2002-01-24	2003-07-31	Sofotec Gmbh & Co Kg	Patrone für einen Pulverinhalator
US7258118B2 (en) *	2002-01-24	2007-08-21	Sofotec Gmbh & Co, Kg	Pharmaceutical powder cartridge, and inhaler equipped with same
PE20040844A1 (es)	2002-11-26	2004-12-30	Novartis Ag	Acidos fenilaceticos y derivados como inhibidores de la cox-2
US7071355B2 (en)	2002-12-23	2006-07-04	4 Sc Ag	Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056747A1 (en) *	2002-12-23	2004-07-08	4Sc Ag	Dhodh-inhibitors and method for their identification
SE0400234D0 (sv) *	2004-02-06	2004-02-06	Active Biotech Ab	New compounds, methods for their preparation and use thereof
BRPI0511290A (pt)	2004-05-21	2007-12-18	Uab Research Foundation	composições e métodos referentes aos inibidores da sìntese da pirimidina
WO2006022442A1 (ja)	2004-08-24	2006-03-02	Santen Pharmaceutical Co., Ltd.	ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006044741A1 (en)	2004-10-19	2006-04-27	Aventis Pharmaceuticals Inc.	Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
PE20081200A1 (es)	2006-12-04	2008-11-06	Bayer Schering Pharma Ag	Sal de potasio cristalina de analogos de lipoxina a4
ES2319596B1 (es) *	2006-12-22	2010-02-08	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
NZ579040A (en) *	2007-02-06	2011-01-28	Chelsea Therapeutics Inc	New compounds, methods for their preparation and use thereof
UY31272A1 (es) *	2007-08-10	2009-01-30	Almirall Lab	Nuevos derivados de ácido azabifenilaminobenzoico
EP2210615A1 (en) *	2009-01-21	2010-07-28	Almirall, S.A.	Combinations comprising methotrexate and DHODH inhibitors
EP2239256A1 (en) *	2009-03-13	2010-10-13	Almirall, S.A.	Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2228367A1 (en) *	2009-03-13	2010-09-15	Almirall, S.A.	Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en)	2009-03-13	2010-09-22	Almirall, S.A.	Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2314577A1 (en) *	2009-10-16	2011-04-27	Almirall, S.A.	Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

2008
- 2008-06-20 EP EP08382022A patent/EP2135610A1/en not_active Withdrawn
2009
- 2009-06-12 UY UY031897A patent/UY31897A1/es not_active Application Discontinuation
- 2009-06-17 TW TW098120322A patent/TWI440462B/zh not_active IP Right Cessation
- 2009-06-18 UA UAA201100428A patent/UA114388C2/uk unknown
- 2009-06-18 HR HRP20171667TT patent/HRP20171667T1/hr unknown
- 2009-06-18 AR ARP090102209A patent/AR072174A1/es not_active Application Discontinuation
- 2009-06-18 EA EA201100028A patent/EA020193B1/ru unknown
- 2009-06-18 JP JP2011513952A patent/JP5507551B2/ja not_active Expired - Fee Related
- 2009-06-18 AU AU2009259625A patent/AU2009259625B2/en not_active Ceased
- 2009-06-18 ME MEP-2017-245A patent/ME02903B/me unknown
- 2009-06-18 SG SG2013030663A patent/SG189810A1/en unknown
- 2009-06-18 KR KR1020107027084A patent/KR101675601B1/ko not_active Expired - Fee Related
- 2009-06-18 NZ NZ589089A patent/NZ589089A/xx not_active IP Right Cessation
- 2009-06-18 US US12/999,698 patent/US8865728B2/en active Active
- 2009-06-18 ES ES09765623.5T patent/ES2641168T3/es active Active
- 2009-06-18 DK DK09765623.5T patent/DK2296663T3/en active
- 2009-06-18 EP EP09765623.5A patent/EP2296663B1/en active Active
- 2009-06-18 CN CN200980123300.6A patent/CN102065866B/zh not_active Expired - Fee Related
- 2009-06-18 NO NO09765623A patent/NO2296663T3/no unknown
- 2009-06-18 WO PCT/EP2009/004404 patent/WO2009153043A1/en not_active Ceased
- 2009-06-18 RS RS20171054A patent/RS56584B1/sr unknown
- 2009-06-18 PE PE2010001062A patent/PE20110149A1/es active IP Right Grant
- 2009-06-18 PT PT97656235T patent/PT2296663T/pt unknown
- 2009-06-18 MY MYPI2010006038A patent/MY155249A/en unknown
- 2009-06-18 MX MX2010013409A patent/MX2010013409A/es unknown
- 2009-06-18 BR BRPI0909995A patent/BRPI0909995A2/pt not_active Application Discontinuation
- 2009-06-18 PL PL09765623T patent/PL2296663T3/pl unknown
- 2009-06-18 HU HUE09765623A patent/HUE036639T2/hu unknown
- 2009-06-18 CA CA2728976A patent/CA2728976C/en active Active
- 2009-06-18 SG SG10201609515RA patent/SG10201609515RA/en unknown
- 2009-06-18 LT LTEP09765623.5T patent/LT2296663T/lt unknown
- 2009-06-18 SI SI200931742T patent/SI2296663T1/sl unknown
2010
- 2010-11-10 ZA ZA2010/08041A patent/ZA201008041B/en unknown
- 2010-11-11 IL IL209267A patent/IL209267A/en active IP Right Grant
- 2010-11-16 CO CO10143337A patent/CO6321267A2/es active IP Right Grant
- 2010-12-06 CL CL2010001359A patent/CL2010001359A1/es unknown
2017
- 2017-11-08 CY CY20171101170T patent/CY1119643T1/el unknown

Also Published As

Publication number	Publication date
TWI440462B (zh)	2014-06-11
NO2296663T3 (lt)	2018-01-13
UA114388C2 (uk)	2017-06-12
CA2728976A1 (en)	2009-12-23
HUE036639T2 (hu)	2018-07-30
KR101675601B1 (ko)	2016-11-11
CY1119643T1 (el)	2018-04-04
MX2010013409A (es)	2010-12-22
HRP20171667T1 (hr)	2017-12-15
KR20110036530A (ko)	2011-04-07
CN102065866A (zh)	2011-05-18
PT2296663T (pt)	2017-09-11
EA020193B1 (ru)	2014-09-30
AR072174A1 (es)	2010-08-11
ZA201008041B (en)	2011-06-29
ME02903B (me)	2018-10-20
US8865728B2 (en)	2014-10-21
NZ589089A (en)	2012-12-21
SG10201609515RA (en)	2017-01-27
EP2135610A1 (en)	2009-12-23
SG189810A1 (en)	2013-05-31
PL2296663T3 (pl)	2018-04-30
IL209267A0 (en)	2011-01-31
EP2296663B1 (en)	2017-08-16
JP2011524392A (ja)	2011-09-01
CA2728976C (en)	2017-10-17
IL209267A (en)	2017-07-31
TW201000103A (en)	2010-01-01
CO6321267A2 (es)	2011-09-20
UY31897A1 (es)	2009-08-31
EA201100028A1 (ru)	2011-08-30
DK2296663T3 (en)	2017-10-30
BRPI0909995A2 (pt)	2015-10-20
AU2009259625B2 (en)	2015-01-15
PE20110149A1 (es)	2011-03-07
MY155249A (en)	2015-09-30
CL2010001359A1 (es)	2011-04-08
AU2009259625A1 (en)	2009-12-23
CN102065866B (zh)	2014-03-26
ES2641168T3 (es)	2017-11-08
WO2009153043A1 (en)	2009-12-23
JP5507551B2 (ja)	2014-05-28
RS56584B1 (sr)	2018-02-28
US20110129445A1 (en)	2011-06-02
SI2296663T1 (sl)	2017-11-30
EP2296663A1 (en)	2011-03-23

Publication	Publication Date	Title
IL209267A0 (en)	2011-01-31	Combinations comprising methotrexate and dhodh inhibitors
IL213625A0 (en)	2011-07-31	Combinations comprising methotrexate and dhodh inhibitors
IL210804A0 (en)	2011-04-28	Deacetylase inhibitors and uses thereof
ZA201101586B (en)	2012-05-30	Aminotriazolopyridines and their use as kinase inhibitors
EP2200977A4 (en)	2011-12-28	F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS
LT2318366T (lt)	2017-10-25	Psma surišantys agentai ir jų panaudojimas
IL211742A0 (en)	2011-06-30	Frizzled-binding agents and uses thereof
IL210734A0 (en)	2011-03-31	cMET INHIBITORS
IL213000A0 (en)	2011-07-31	Raf inhibitors and their uses
IL207415A0 (en)	2010-12-30	Protein kinase inhibitors and use thereof
IL208483A (en)	2014-02-27	2 limk inhibitors and preparations containing them
ZA201003420B (en)	2011-08-31	Protein kinase inhibitors and use thereof
IL209407A0 (en)	2011-01-31	Selective caspase inhibitors and uses thereof
EP2291377A4 (en)	2011-10-05	IMIDAZOPYRIMIDINONE AND ITS USES
ZA201103456B (en)	2012-08-29	Leukolectins and uses thereof
PL2247601T3 (pl)	2013-09-30	Tiazopirymidynony i ich zastosowanie
GB0918601D0 (en)	2009-12-09	Decahydro-1H-Indenoquinolinone and decahydro-3H-cyclopenaphenanthridinone CYP17 inhibitors
ZA201102837B (en)	2011-12-28	Phosphodiestarase inhibitors
IL208824A0 (en)	2011-01-31	Iminopyridine derivative and use thereof
HK1159528A (en)	2012-08-03	Combinations comprising methotrexate and dhodh inhibitors
HU0800405D0 (en)	2008-08-28	Ewnvironment-friendly biocidis and use thereof
GB0810609D0 (en)	2008-07-16	Methods and uses
GB0816523D0 (en)	2008-10-15	Methods and uses
IL214333A0 (en)	2011-09-27	Carbamoylphosphonates as inhibitors and uses thereof
GB0808857D0 (en)	2008-06-25	Methdos and uses